Business Description
Nicox SA
ISIN : FR0013018124
Share Class Description:
LTS:0RCQ: Share from reverse splitTotal Employee Number:
10Compare
Compare
Traded in other countries / regions
ALCOX.FranceNXOA.Germany0RCQ.UKNICXF.USA IPO Date
2008-04-02Description
Nicox SA is an international ophthalmology company developing solutions to help preserve vision and improve ocular health. It is developing a portfolio of treatments targeting glaucoma, diseases of the anterior segment and retinal diseases. A drug candidate (NCX 470) in phase 3 clinical development designed to reduce intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension. A drug candidate (NCX 1728) in preclinical development for retinal diseases and glaucoma, derived from Nicox's proprietary nitric oxide (NO)-donating research platform. Its products are ZERVIATE, VYZULTA, Naproxcinod, etc.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 10.19 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 0.02 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -64.37 | |||||
Beneish M-Score | -4.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 25.8 | |||||
3-Year EPS without NRI Growth Rate | 30.9 | |||||
3-Year Book Growth Rate | -56.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 76.03 | |||||
9-Day RSI | 65.19 | |||||
14-Day RSI | 59.35 | |||||
3-1 Month Momentum % | -8.09 | |||||
6-1 Month Momentum % | 4.17 | |||||
12-1 Month Momentum % | 67.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.18 | |||||
Quick Ratio | 4.18 | |||||
Cash Ratio | 1.69 | |||||
Days Sales Outstanding | 26.31 | |||||
Days Payable | 41.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.7 | |||||
Shareholder Yield % | 36.75 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 38.99 | |||||
Operating Margin % | -81.34 | |||||
Net Margin % | -14.39 | |||||
EBITDA Margin % | 112.75 | |||||
ROE % | -155.68 | |||||
ROA % | -14.65 | |||||
ROIC % | -124.21 | |||||
3-Year ROIIC % | -37.83 | |||||
ROC (Joel Greenblatt) % | 27.47 | |||||
ROCE % | 6.12 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 2.88 | |||||
Price-to-Owner-Earnings | 1.92 | |||||
PS Ratio | 2.14 | |||||
PB Ratio | 6.12 | |||||
Price-to-Tangible-Book | 5.6 | |||||
EV-to-EBIT | 61.49 | |||||
EV-to-EBITDA | 1.75 | |||||
EV-to-Revenue | 1.97 | |||||
EV-to-Forward-Revenue | 10.62 | |||||
Price-to-GF-Value | 0.55 | |||||
Price-to-Median-PS-Value | 0.19 | |||||
| Price-to-Net-Current-Asset-Value | 5.6 | |||||
Earnings Yield (Greenblatt) % | 1.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nicox SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 16.771 | ||
| EPS (TTM) (€) | -0.049 | ||
| Beta | 1.9193 | ||
| 3-Year Sharpe Ratio | 0.1 | ||
| 3-Year Sortino Ratio | 0.18 | ||
| Volatility % | 67.87 | ||
| 14-Day RSI | 59.35 | ||
| 14-Day ATR (€) | 0.011333 | ||
| 20-Day SMA (€) | 0.37125 | ||
| 12-1 Month Momentum % | 67.41 | ||
| 52-Week Range (€) | 0.222 - 0.65 | ||
| Shares Outstanding (Mil) | 93.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nicox SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nicox SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2024 | 2024-07-19 | 0.18 (+0.00%) | ||
| 0.2:1 Stock Split | 2015-12-03 | 8.35 (+0.00%) |
Show
Entries
Nicox SA Frequently Asked Questions
What is Nicox SA(LTS:0RCQ)'s stock price today?
The current price of LTS:0RCQ is €0.39. The 52 week high of LTS:0RCQ is €0.65 and 52 week low is €0.22.
When is next earnings date of Nicox SA(LTS:0RCQ)?
The next earnings date of Nicox SA(LTS:0RCQ) is .
Does Nicox SA(LTS:0RCQ) pay dividends? If so, how much?
Nicox SA(LTS:0RCQ) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea | 2021-02-09 |
Articles on Nicox SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers